focus -WSS

focus

author：focus 2025-09-27 23:52:00 - browse：87

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Bird flu in dairy cattle: New measures to control spread to humans

leisure time

WSS

Medicare Advantage 2025 payments will dip, Biden administration says

Scientific mystery highlights the blind spots in genomics databases

AI used to predict Covid

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Hundreds died while taking an arthritis drug, but nobody alerted patients

Four alarming medical procedures we’re glad history forgot

focus

focus

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Peter Hotez and the public health issue of online harassment

Do more moles mean more problems? Not so, says new study

Moonlake's readout produced a cash windfall. Risks remain

Akili, maker of video game for ADHD, to be acquired for 34 million

Medical records are filled with copy

Trial using CRISPR to edit HIV out of cells disappoints

Jerome Adams on the need for new antivirals for Covid

Young boy dies in trial for Pfizer Duchenne gene therapy

entertainment

People with mental disorders often marry others with same

iTeos Therapeutics debuts first data on TIGIT

Study: Black kids more likely to die after surgery than white kids

Focused ultrasound for uterine fibroids: an uphill battle

Multiple sclerosis has subtypes with different best treatments: study

Startling documents reveal new facets of Sacklers' opioid empire

entertainment

leisure time

explore

hotspot